Apimeds Pharmaceuticals US, Inc. SEC filings APUS
Apimeds Pharmaceuticals US, Inc. has 130 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form 10-K, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 23, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Other events
|
Aug 6, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Officer or director change
|
May 5, 2026 | May 5, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
May 4, 2026 | Apr 24, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 22, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Other events
|
Apr 16, 2026 | Apr 15, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Apr 9, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Mar 26, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Mar 25, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Other events
|
Mar 16, 2026 | Mar 16, 2026 |
| 8-K/A |
Amended current report
Acquisition or sale of assets
|
Feb 17, 2026 | Dec 1, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 10, 2025 | Dec 5, 2025 |
| 8-K/A |
Amended current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Dec 10, 2025 | Dec 1, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Dec 2, 2025 | Dec 1, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 18, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 16, 2025 | Oct 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 16, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2025 | May 30, 2025 |
| 8-K |
Current report
Material agreement
|
May 20, 2025 | May 16, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 12, 2025 | May 8, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 15, 2025 | Apr 11, 2025 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Matawan, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1894525
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.